Literature DB >> 17143744

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?

Tien Huu Nguyen1, Martin S Lennard, Cyrus Ghobadi, Amin Rostami-Hodjegan, William L Ledger.   

Abstract

PURPOSE: To determine whether ovarian response to previous clomifene treatment could influence the selection of the starting dose of gonadotropins in subsequent in vitro fertilization (IVF) or intra uterine insemination (IUI).
METHODS: Forty three anovular women who had received clomifene for ovulation induction followed by gonadotropins for IUI or IVF superovulation were reviewed retrospectively. Data on gonadotropin dose were compared between clomifene-resistant patients and clomifene responders.
RESULTS: IVF patients who had had prior superovulation/IUI treatment received similar doses of gonadotropins regardless of response to clomifene (1610 IU versus 1560 IU, p = 0.74). In IVF patients not receiving prior IUI treatment, the clomifene-resistant women were given higher doses of gonadotropins than those responding to clomifene (2500 IU versus 1440 IU, p = 0.042).
CONCLUSIONS: We found that, in our Unit, clinicians appeared to use prior non-response to clomifene as a reason for prescribing a higher starting dose of gonadotropins in IVF treatment, a practice that is not evidence-based.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143744      PMCID: PMC3455097          DOI: 10.1007/s10815-006-9065-x

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  8 in total

1.  A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.

Authors:  H J Out; S Lindenberg; A L Mikkelsen; T Eldar-Geva; D L Healy; A Leader; F J Rodriguez-Escudero; J A Garcia-Velasco; A Pellicer
Journal:  Hum Reprod       Date:  1999-03       Impact factor: 6.918

2.  Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation.

Authors:  Z Ben-Rafael; J F Strauss; L Mastroianni; G L Flickinger
Journal:  Fertil Steril       Date:  1986-10       Impact factor: 7.329

3.  The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization.

Authors:  P Devroey; H Tournaye; A Van Steirteghem; P Hendrix; H J Out
Journal:  Hum Reprod       Date:  1998-03       Impact factor: 6.918

4.  A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.

Authors:  M Wikland; C Bergh; K Borg; T Hillensjö; C M Howles; A Knutsson; L Nilsson; M Wood
Journal:  Hum Reprod       Date:  2001-08       Impact factor: 6.918

5.  Endocrinological and endometrial factors in recurrent miscarriage.

Authors:  T C Li; M D Spuijbroek; E Tuckerman; B Anstie; M Loxley; S Laird
Journal:  BJOG       Date:  2000-12       Impact factor: 6.531

6.  Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study.

Authors:  M H van Hooff; A T Alberda; G J Huisman; G H Zeilmaker; R A Leerentveld
Journal:  Hum Reprod       Date:  1993-03       Impact factor: 6.918

7.  A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.

Authors:  Peter Y K Yong; Sandra Brett; David T Baird; K J Thong
Journal:  Fertil Steril       Date:  2003-02       Impact factor: 7.329

8.  Gonadotrophins in ovulation induction.

Authors:  N S Macklon; B C J M Fauser
Journal:  Reprod Biomed Online       Date:  2005-06       Impact factor: 3.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.